Published 2026-06-24
Summary: The FDA reportedly dropped its complaint against Whoop regarding its blood-pressure tracking tool, following an initial enforcement action that urged Whoop to disable the feature. The development marks a shift in regulatory stance toward the company’s Blood Pressure Insights and related capabilities.
What We Know
- The FDA issued a warning letter to Whoop, Inc. concerning Blood Pressure Insights (BPI), signaling initial regulatory concerns about the feature.
- There is reporting that the FDA subsequently dropped its complaint against Whoop’s blood-pressure tracking tool, indicating an about-face in enforcement.
- Public-facing sources reference an FDA warning letter dated mid-2025 and a later Bloomberg report about the complaint being dropped in 2026.
What’s Still Unclear
- Exact status and date of the FDA’s complaint dismissal beyond the Bloomberg report date.
- Whether the FDA’s drop refers to the same Blood Pressure Insights feature or to a related tool within Whoop’s offerings.
- Current FDA enforcement stance or ongoing objections, if any, after the reported drop.
Context
Contextual background involves regulatory scrutiny of consumer health tech features that provide biometric tracking. Agencies have historically evaluated whether such features meet medical device definitions and applicable safety and efficacy expectations, balancing consumer wellness use with potential clinical implications.
Why It Matters
Regulatory decisions shape how consumer wearables and health-tech features can market and position themselves, potentially influencing user trust, feature availability, and future development of diagnostic or monitoring capabilities.
What to Watch Next
- Any official FDA statements or updates clarifying the regulatory status of Whoop’s Blood Pressure Insights.
- Company communications detailing how the feature will be positioned or updated in light of regulatory developments.
- Industry reaction from other health-tech firms regarding regulatory expectations for blood-pressure or other biometric tracking tools.
FAQ
Q: What happened with the FDA’s complaint against Whoop?
A: Reports indicate the FDA dropped the complaint related to Whoop’s blood-pressure tracking tool, after an initial enforcement action, but exact details and timing beyond the cited reports are not confirmed in available information.
Q: Does this affect ongoing features or future updates?
A: Not confirmed in the available information; any impact would depend on official FDA communications and company responses.
Related coverage
- Defence startup kamikaze drones funding sparks EU military
- Qualcomm Modular acquisition talks intensify AI chip
- South Korea export growth robustness shines in early June
Source Transparency
- This article is based on a short preliminary brief and may not reflect the full details available in ongoing reporting.
- Source links are provided in the Sources section where available.
- A limited open-web check was used to clarify key details when possible; unclear items remain clearly marked.
Original brief: The FDA dropped its complaint against Whoop over its blood-pressure tracking tool, marking an about-face after the agency initially asked the company to disable it…
Sources
- WHOOP, Inc. – 709755 – 07/14/2025 | FDA
- FDA Drops Complaint Against Whoop's Blood Pressure Tracking Tool
- Whoop refuses to back down after FDA calls blood pressure feature a …
- Whoop says FDA is 'overstepping' with blood pressure feature warning – CNBC
- The FDA Says Whoop's Blood Pressure Feature Is Illegal, but It's Still …